open access

Vol 19, No 5 (2014)
Reviews
Published online: 2014-09-01
Submitted: 2013-04-09
Get Citation

Radiotherapy for Stage IIA seminoma: The Northern Israel Oncology Center Experience, 1971–2010

Moshe E. Stein, Jamal Zidan, Tomer Charas, Rahamim Ben-Yosef
DOI: 10.1016/j.rpor.2014.02.004
·
Rep Pract Oncol Radiother 2014;19(5):281-286.

open access

Vol 19, No 5 (2014)
Reviews
Published online: 2014-09-01
Submitted: 2013-04-09

Abstract

Aim

To evaluate treatment details, outcome, relapse rate and side-effects in Stage IIA seminoma irradiated and followed for a period of 39 years.

Background

Seminoma is a very radiosensitive disease and radiation therapy alone is able to achieve long-term disease-free survival, even in advanced Stage disease. Due to the lack of long-term prospective studies, it is of value to follow patients and try to determine the appropriate volume to be irradiated and the dose which can achieve total cure with minimal acute and chronic side-effects.

Patients and methods

A retrospective review of 24 Stage IIA seminoma patients irradiated between 1971 and 2010 was performed. All patients underwent orchiectomy and meticulous clinical, biochemical and radiological staging.

Results

Median age at diagnosis was 36 years and median follow-up was 84 months. A majority of patients received the “hockey-stick” irradiation schedule (para-aortic lymph nodes and hemi-pelvis) to a total dose of 2250–2500[[ce:hsp sp="0.25"/]]cGy and a boost to radiologically involved nodes of 500–1000[[ce:hsp sp="0.25"/]]cGy. Treatment was well-tolerated. Twenty-one (88%) patients are alive with no evidence of disease. Two patients died due to unknown causes, while one patient died due to head of the pancreas carcinoma, most probably radiation-induced.

Conclusions

In Stage II seminoma, radiotherapy can provide excellent results with low rates of toxicity. Reduction of total dose and size of fields without affecting the good results should be considered. Due to prolonged survival, awareness of second primary tumor is indicated.

Abstract

Aim

To evaluate treatment details, outcome, relapse rate and side-effects in Stage IIA seminoma irradiated and followed for a period of 39 years.

Background

Seminoma is a very radiosensitive disease and radiation therapy alone is able to achieve long-term disease-free survival, even in advanced Stage disease. Due to the lack of long-term prospective studies, it is of value to follow patients and try to determine the appropriate volume to be irradiated and the dose which can achieve total cure with minimal acute and chronic side-effects.

Patients and methods

A retrospective review of 24 Stage IIA seminoma patients irradiated between 1971 and 2010 was performed. All patients underwent orchiectomy and meticulous clinical, biochemical and radiological staging.

Results

Median age at diagnosis was 36 years and median follow-up was 84 months. A majority of patients received the “hockey-stick” irradiation schedule (para-aortic lymph nodes and hemi-pelvis) to a total dose of 2250–2500[[ce:hsp sp="0.25"/]]cGy and a boost to radiologically involved nodes of 500–1000[[ce:hsp sp="0.25"/]]cGy. Treatment was well-tolerated. Twenty-one (88%) patients are alive with no evidence of disease. Two patients died due to unknown causes, while one patient died due to head of the pancreas carcinoma, most probably radiation-induced.

Conclusions

In Stage II seminoma, radiotherapy can provide excellent results with low rates of toxicity. Reduction of total dose and size of fields without affecting the good results should be considered. Due to prolonged survival, awareness of second primary tumor is indicated.

Get Citation

Keywords

Long-term survival; Radiation therapy; Stage IIA seminoma

About this article
Title

Radiotherapy for Stage IIA seminoma: The Northern Israel Oncology Center Experience, 1971–2010

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 19, No 5 (2014)

Pages

281-286

Published online

2014-09-01

DOI

10.1016/j.rpor.2014.02.004

Bibliographic record

Rep Pract Oncol Radiother 2014;19(5):281-286.

Keywords

Long-term survival
Radiation therapy
Stage IIA seminoma

Authors

Moshe E. Stein
Jamal Zidan
Tomer Charas
Rahamim Ben-Yosef

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl